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ABSTRACT. The metal complexes {Ni (II), Co (II) and Mn (II)} of 3-(2-(aryl)hydrazono)acetylacetone with 
isatin were synthesized and screened for their in vitro antibacterial activity against four pathogenic 
microorganisms {two Gram‐positive and two Gram negative}. The results of antibacterial activities revealed that 
all the metal complexes 1-9 exhibited moderate activities. Also, Lipinski's rule of five (RO5) of the mixed ligand 
metal complexes were calculated by SwissADME website. 
  




There is recently a growing interest in the field of synthesizing mixed ligand metal complexes 
due to various biological applications. In 2018, Sakr et al. have prepared Zn(II), Sn(II) and 
Ce(III) of gemifloxacin with glycine (A) as antibacterial agents [1]. Also, in 2017, Omar et al., 
have prepared the complexes of Mn(II), Co(II), Ni(II) and Zn(II) of Schiff base and 
2,2′‐bipyridine (B) for evaluation their antimicrobial and anticancer activities [2]. Literature 
survey revealed that isatin and its derivatives show a wide range of biological applications [3-5] 
such as 1-(1-(3-methylbenzyl)-2-oxoindolin-3-ylidene)-thiosemicarbazide (C) showed highly 
active against Mycobacterium bovis bacillus Calmette-Guerin [6] and 3-(benzylimino)-7-
chloroindolin-2-one (D) display significant cytotoxic activity against HeLa, SK-BR-3 and MCF-
7 cells [7]. Also, there are some isatin-based drugs, e.g. Sunitinib (Sutent®) (E) acts as tyrosine 
kinase inhibitor [8]. Nintedanib (F) acts as triple angiokinase inhibitor [9] (Figure 1). In 
addition, arylhydrazono-1,3-diketone derivatives are useful synthons in the synthesis of a large 
number of biologically compounds [10-12]. 
In view of these facts and in continuation of our target [13-25], the metal complexes {Ni(II), 
Co(II) and Mn(II)} of 3-(2-(aryl)hydrazono)acetylacetone with isatin have been synthesized to 
evaluate their antibacterial activity against four pathogenic microorganisms {two Gram‐positive 
(Bacillus subtilis and Staphylococcus aureus) and two Gram negative (Escherichia coli and 
Pseudomonas aeruginosa)}. Also, the study has been extended to calculate the physicochemical 
properties and drug-likeness (Lipinski's rule) of the mixed ligand metal complexes (Figure 2). 
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Drug-likeness (Lipinski's rule)  
 




Preparation of 3-(arylhydrazono)acetylacetone (HL) 
 
The 3-(arylhydrazono)acetylacetone derivatives (HL) were prepared by coupling acetylactone 
with different diazonium salts, where acetylactone (0.01 mol) was placed in a beaker containing 
ethanol (50 mL) and sodium acetate (5 g) then the diazonium salt (0.01 mol) was added with 
stirring. The reaction proceeded at 0-5 °C for 30 min. The 3-(arylhydrazono)acetylacetone 
derivatives were precipitated and collected by filtration, washed with cold deionized water and 
recrystallized from ethanol [26-28]. 
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3-(2-Phenylhydrazono)acetylacetone (HL1). Yellow needles; yield: 86%; m.p. 86-87 ºC; anal. 
calcd. (%) for C11H12N2O2 (204.23): C, 64.69; H, 5.92; N, 13.72. Found: C, 64.50; H, 6.10; N, 
13.65%; IR (KBr) νmax/cm
-1 3430-3092 (N-H…O=C, hydrogen bonded), 1673 (C=O, free), 1623 
(C=O, hydrogen bonded), 1593 (C=N), 1518 (N-H); 1H NMR (DMSO-d6, δ ppm) 2.36 (s, 3H, 
CH3CO free), 2.43 (s, 3H, CH3CO hydrogen bonded), 7.16 (t, 1H, aromatic), 7.27 (t, 2H, 
aromatic), 7.52 (d, 2H, J=8.5 Hz, aromatic), 14.02 (s, 1H, NH, D2O exchangeable). 
 
3-(2-(4-Chlorophenyl)hydrazono)acetylacetone (HL2). Yellow needles; yield: 86%; m.p. 147-
148 ºC; anal. calcd. (%) for C11H11ClN2O2 (238.67): C, 55.36; H, 4.65; N, 11.74. Found: C, 
55.50; H, 4.52; N, 11.80%; IR (KBr) νmax/cm
-1 3432-3094 (N-H…O=C, hydrogen bonded), 
1667 (C=O, free), 1625 (C=O, hydrogen bonded), 1589 (C=N), 1519 (N-H); 1H NMR 
(DMSO-d6, δ ppm) 2.37 (s, 3H, CH3CO free), 2.42 (s, 3H, CH3CO hydrogen bonded), 7.43 (d, 
2H, J = 8.4 Hz, aromatic), 7.57 (d, 2H, J = 8.4 Hz, aromatic), 13.81 (s, 1H, NH, D2O 
exchangeable). 
 
3-(2-(4-Bromophenyl)hydrazono)acetylacetone (HL3). Yellow needles; yield 86%; m.p. 141-
142 ºC; anal. calcd. (%) for C11H11BrN2O2 (283.12): C, 46.66; H, 3.92; N, 9.89. Found: C, 46.50; 
H, 4.10; N, 10.00%; IR (KBr) νmax/cm
-1 3422-3073 (N-H…O=C, hydrogen bonded), 1667 
(C=O, free), 1623 (C=O, hydrogen bonded), 1585 (C=N), 1513 (N-H); 1H NMR (DMSO-d6, δ 
ppm) 2.37 (s, 3H, CH3CO free), 2.42 (s, 3H, CH3CO hydrogen bonded), 7.50 (d, 2H, J = 9.15 
Hz, aromatic), 7.56 (d, 2H, J = 9.15 Hz, aromatic), 13.75 (s, 1H, NH, D2O exchangeable). 
 
Isatin (L'). IR (KBr) νmax/cm
-1 3191 (N-H), 1745 (C=O), 1731 (C=O); 1H NMR (DMSO-d6, δ 
ppm) 6.88 (d, 1H, J = 7.7 Hz, aromatic), 7.03 (t, 1H, aromatic), 7.46 (d, 1H, J = 7.7 Hz, 
aromatic), 7.54 (t, 1H, aromatic), 10.98 (s, 1H, NH, D2O exchangeable). 
 
Preparation of the complexes 1-9 
 
A solution of the metal chloride (3.4 mmol) in a minimum amount of water was added to a hot 
solution of the mixed ligand in methanol (3.4 mmol each). A clear solution was obtained. The 
pH was raised from 6.0 to 8.0 with dilute NaOH solution. The mixture was refluxed with 
stirring for 6 hours. The formed complex was filtered off, washed several times with hot 
methanol and dried under reduced pressure [29]. 
 
[NiL'L1(OH)(H2O)] (1). Greenish yellow; yield 50%; m.p. 215-218 ºC; anal. calcd. (%) for 
C19H19N3NiO6 (444.06): C, 51.39; H, 4.31; N, 9.46. Found: C, 51.50; H, 4.25; N, 9.55%; IR 
(KBr) νmax/cm
-1 3522 (O-H), 3181 (N-H, L'), 1717 (C=O, L'), 1709 (C=O, L'), 1667 (C=O free, 
L1), 1600 (C=O coordinated, L1), 1590 (C=N, L1), 583 (Ni-N), 493 (Ni-O); 1H NMR (DMSO-
d6, δ ppm) 2.34 (s, 3H, CH3CO free, L
1), 2.64 (s, 3H, CH3CO coordinated, L
1), 6.76-7.58 (m, 
9H, aromatic, L' and L1), 10.20 (s, 1H, NH, D2O exchangeable, L'); UV-Vis.  = 963, 576, 420 
nm; magnetic moment (µeff/B.M.): 3.17; molar conductivity (Ω
-1 cm2 mol-1): 11.6. 
 
[CoL’L1(OH)(H2O)] (2). Dark green; yield 53%; m.p. 209-211 ºC; anal. calcd. (%) for 
C19H19CoN3O6 (444.30): C, 51.36; H, 4.31; N, 9.46. Found: C, 51.55; H, 4.25; N, 9.55%; IR 
(KBr) νmax/cm
-1 3580 (O-H), 3183 (N-H, L'), 1715 (C=O, L'), 1707 (C=O, L'), 1669 (C=O free, 
L1), 1602 (C=O coordinated, L1), 1591 (C=N, L1), 584 (Co-N), 491 (Co-O); UV-Vis.  = 654, 
540 nm; magnetic moment (µeff/B.M.): 4.92; molar conductivity (Ω
-1 cm2 mol-1): 12.8. 
 
[MnL’L1(OH)(H2O)] (3). Green; yield 45%; m.p. 210-212 ºC; anal. calcd. (%) for 
C19H19MnN3O6 (440.31): C, 51.83; H, 4.35; N, 9.54. Found: C, 51.70; H, 4.40; N, 9.47%; IR 
(KBr) νmax/cm
-1 3544 (O-H), 3182 (N-H, L'), 1719 (C=O, L'), 1711 (C=O, L'), 1661 (C=O free, 
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L1), 1605 (C=O coordinated, L1), 1590 (C=N, L1), 540 (Mn-N), 487 (Mn-O); UV-Vis.  = 752, 
618, 520 nm; magnetic moment (µeff/B.M.): 5.82; molar conductivity (Ω
-1 cm2 mol-1): 15.4. 
 
[NiL'L2(OH)(H2O)] (4). Greenish yellow; yield 60%; m.p. 217-220 ºC; anal. calcd. (%) for 
C19H18ClN3NiO6 (478.51): C, 47.69; H, 3.79; N, 8.78. Found: C, 47.50; H, 3.70; N, 8.70%; IR 
(KBr) νmax/cm
-1 3565 (O-H), 3180 (N-H, L'), 1715 (C=O, L'), 1707 (C=O, L'), 1661 (C=O free, 
L2), 1605 (C=O coordinated, L2), 1585 (C=N, L2), 579 (Ni-N), 448 (Ni-O); 1H NMR (DMSO-
d6, δ ppm) 2.30 (s, 3H, CH3CO free, L
2), 2.60 (s, 3H, CH3CO coordinated, L
2), 6.74-7.60 (m, 
8H, aromatic, L' and L2), 10.20 (s, 1H, NH, D2O exchangeable, L'); UV-Vis.  = 988, 581, 422 
nm; magnetic moment (µeff/B.M.): 3.20; molar conductivity (Ω
-1 cm2 mol-1): 20.5. 
 
[CoL'L2(OH)(H2O)] (5). Dark green; yield 58%; m.p. 207-209 ºC; anal. calcd. (%) for 
C19H18ClCoN3O6 (478.75): C, 47.67; H, 3.79; N, 8.78. Found: C, 47.50; H, 3.85; N, 8.70%; IR 
(KBr) νmax/cm
-1 3553 (O-H), 3186 (N-H, L'), 1716 (C=O, L'), 1708 (C=O, L'), 1662 (C=O free, 
L2), 1602 (C=O coordinated, L2), 1584 (C=N, L2), 572 (Co-N), 438 (Co-O); UV-Vis.  = 661, 
548 nm; magnetic moment (µeff/B.M.): 4.94; molar conductivity (Ω
-1 cm2 mol-1): 22.1. 
 
[MnL'L2(OH)(H2O)] (6). Greenish yellow; yield 55%; m.p. 216-219 ºC; anal. calcd. (%) for 
C19H18ClMnN3O6 (474.75): C, 48.07; H, 3.82; N, 8.85. Found: C, 48.20; H, 3.75; N, 8.80%; IR 
(KBr) νmax/cm
-1 3550 (O-H), 3183 (N-H, L'), 1718 (C=O, L'), 1710 (C=O, L'), 1661 (C=O free, 
L2), 1605 (C=O coordinated, L2), 1580 (C=N, L2), 569 (Mn-N), 444 (Mn-O); 1H NMR 
(DMSO-d6, δ ppm) 2.33 (s, 3H, CH3CO free, L
2), 2.61 (s, 3H, CH3CO coordinated, L
2), 6.74-
7.58 (m, 8H, aromatic, L' and L2), 10.21 (s, 1H, NH, D2O exchangeable, L'); UV-Vis.  = 758, 
622, 526 nm; magnetic moment (µeff/B.M.): 5.90; molar conductivity (Ω
-1 cm2 mol-1): 19.8. 
 
[NiL'L3(OH)(H2O)](7). Greenish yellow; yield 53%; m.p. 223-226 ºC; anal. calcd. (%) for 
C19H18BrN3NiO6 (522.96): C, 43.64; H, 3.47; N, 8.04. Found: C, 43.50; H, 3.55; N, 8.00%; IR 
(KBr) νmax/cm
-1 3575 (O-H), 3184 (N-H, L'), 1722 (C=O, L'), 1711 (C=O, L'), 1660 (C=O free, 
L3), 1600 (C=O coordinated, L3), 1580 (C=N, L3), 578 (Ni-N), 447 (Ni-O); 1H NMR (DMSO-
d6, δ ppm) 2.33 (s, 3H, CH3CO free, L
3), 2.62 (s, 3H, CH3CO coordinated, L
3), 6.75-7.57 (m, 
8H, aromatic, L' and L3), 10.20 (s, 1H, NH, D2O exchangeable, L'); UV-Vis.  = 979, 572, 420 
nm; magnetic moment (µeff/B.M.): 3.19; molar conductivity (Ω
-1 cm2 mol-1): 18.7. 
 
[CoL'L3(OH)(H2O)] (8). Greenish yellow; yield 51%; m.p. 212-215 ºC; anal. calcd. (%) for 
C19H18BrCoN3O6 (523.20): C, 43.62; H, 3.47; N, 8.03. Found: C, 43.80; H, 3.40; N, 8.10%; IR 
(KBr) νmax/cm
-1 3535 (O-H), 3184 (N-H, L'), 1719 (C=O, L'), 1707 (C=O, L'), 1662 (C=O free, 
L3), 1601 (C=O coordinated, L3), 1582 (C=N, L3), 584 (Co-N), 481 (Co-O); UV-Vis.  = 659, 
544 nm; magnetic moment (µeff/B.M.): 4.87; molar conductivity (Ω
-1 cm2 mol-1): 16.9. 
 
[MnL'L3(OH)(H2O)] (9). Green; yield 45%; m.p. 215-218 ºC; anal. calcd. (%) for 
C19H18BrMnN3O6, (519.20): C, 43.95; H, 3.49; N, 8.09. Found: C, 44.10; H, 3.40; N, 8.15%; IR 
(KBr) νmax/cm
-1 3545 (O-H), 3182 (N-H, L'), 1721 (C=O, L'), 1712 (C=O, L'), 1661 (C=O free, 
L3), 1602 (C=O coordinated, L3), 1582 (C=N, L3), 571 (Mn-N), 472 (Mn-O); 1H NMR 
(DMSO-d6, δ ppm) 2.32 (s, 3H, CH3CO free, L
3), 2.60 (s, 3H, CH3CO coordinated, L
3), 6.74-
7.58 (m, 8H, aromatic, L' and L3), 10.21 (s, 1H, NH, D2O exchangeable, L'); UV-Vis.  = 755, 
621, 524 nm; magnetic moment (µeff/B.M.): 5.87; molar conductivity (Ω




Mn(II), Co(II) and Ni(II) complexes of mixed isatin  with 3-(2-(aryl)hydrazono)acetylacetone 1-
9 were screened in vitro for their antibacterial activities against two Gram‐positive bacteria 
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species (Bacillus subtilis, Staphylococcus aureus) and two-Gram negative bacteria species 
(Escherichia coli, Pseudomonas aeruginosa) using a modified Kirby‐Bauer disc diffusion 
method [30]. The bacteria were maintained on Meuller‐Hinton agar. DMSO showed no 
inhibition zone. The agar media were incubated at 35‐37 oC for 24‐48 hours for bacteria. The 
diameter of inhibition zone in millimeter (mm) was measured. Tetracycline is used as a 
reference for antibacterial activities. 
 




3-(Arylhydrazono)acetylacetone (HL) [26-28] is prepared via coupling between diazotized 































3-(Arylhydrazono)acetylacetone (HL) and isatin (L') were reacted with hydrated metal(II) 
chloride in equimolar ratios (1:1:1) for formation the complexes 1-9 having the general 
structural formula [ML′L(OH)(H2O)] (Scheme 2) [29]. 
 
In vitro antibacterial activities 
 
The antibacterial activities of the mixed ligand metal complexes 1-9 against two-Gram negative 
bacteria species (Escherichia coli and Pseudomonas aeruginosa) and two Gram‐positive 
bacteria species (Bacillus subtilis and Staphylococcus aureus) using a modified Kirby‐Bauer 
disc diffusion method [30] are represented in Table 1. The results revealed that the metal 
complexes exhibited moderate activities. 
In case of E. coli (G-), all the mixed metal complexes exhibited moderate activities in the 
range of inhibition zone diameter from 9 to 13 mm. The two complexes 3 and 4 (IZ = 13 mm) 
were more active than all the other tested complexes. In case of P. aeruginosa (G-), the three 
mixed metal complexes 3, 5 and 8 (IZ = 13 mm) were more active than all the other tested 
complexes. By testing the mixed metal complexes against two Gram‐positive bacteria species 
(Bacillus subtilis and Staphylococcus aureus), complex 6 was more potent (IZ = 13 mm) than 
the other tested complexes. 
In general, all the mixed metal complexes 1-9 exhibit moderate activities against the four 
bacteria species used in this study.In particular, the two complexes [MnL’L1(OH)(H2O)] (3) and 
[MnL'L2(OH)(H2O)] (6) which having Mn(II) metal in their structures. May be the introduction 
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the Mn(II) metal in the structure increasing the activities. Therefore, in the future, we will 




























X= H (HL1), Cl (HL2) and Br (HL3)
L, (isatin)
 
Complexes 1-9  
 
Complexes M(II) X Complexes M(II) X 
1 Ni H 6 Mn Cl 
2 Co H 7 Ni Br 
3 Mn H 8 Co Br 
4 Ni Cl 9 Mn Br 




Lipinski's rule of five (RO5) of the mixed ligand metal complexes  
 
Lipinski's rule of five (RO5), is a rule of thumb to evaluate drug likeness or determine if a 
chemical compound with a certain pharmacological or biological activity has chemical 
properties and physical properties that would make it a likely orally active drug in humans. The 
rule was formulated by Christopher A. Lipinski in 1997, based on the observation that most 
orally administered drugs are relatively small and moderately lipophilic molecules [31-32]. 
The molecular weight (MW ≤ 500), lipophilicity (MLogP ≤ 4.15), the number of hydrogen 
bond acceptors (nHBA ≤ 10) and donors (nHBD ≤ 5) of Lipinski’s rule of five were calculated 
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using SwissADME web (http://swissadme.ch/index.php#undefined). The computed molecular 
properties are shown in Table 2. 
 
Table 1. Antibacterial activities of the mixed ligand metal complexes 1-9. 
 
Complexes No. 
Inhibition zone diameter (IZ) in millimeters 
Gram-negative Gram-positive 
E. coli P. aeruginosa B. subtilis S. aureus 
Complex 1 9 10 10 9 
Complex 2 11 11 10 11 
Complex 3 13 13 12 12 
Complex 4 13 12 11 12 
Complex 5 12 13 12 11 
Complex 6 11 12 13 13 
Complex 7 10 9 11 10 
Complex 8 9 13 12 12 
Complex 9 10 10 11 9 
Tetracycline 32 34 32 30 
Compound: >14 mm, significant activity; 7-13 mm, moderate activity; < 7 mm, weak activity. 
 
Table 2. Lipinski's rule of five for the mixed ligand metal complexes 1-9. 
 
The mixed ligand 
metal complexes 
MWa MLogPb nHBAc nHBDd nviolations
e 
Rule <500 ≤4.15 ≤10 ≤5 0 
Complex 1 444.06 -0.86 7 3 0 
Complex 2 444.30 -0.86 7 3 0 
Complex 3 440.31 -0.86 7 3 0 
Complex 4 478.51 -0.36 7 3 0 
Complex 5 478.75 -0.36 7 3 0 
Complex 6 474.75 -0.36 7 3 0 
Complex 7 522.96 -0.25 7 3 1, MW>500 
Complex 8 523.20 -0.25 7 3 1, MW>500 
Complex 9 519.20 -0.25 7 3 1, MW>500 
aMolecular weight; bCalculated lipophillicity (MLog Po/w); 
cNumber of hydrogen bond acceptor; dNumber of 
hydrogen bond donor; eViolations from Lipinski’s Rule. 
 
 From Table 2, all the mixed ligand metal complexes agreement with Lipinski's rule of 
five,where the metal complexes 1-6 in the range of the Lipinski's rule (MW ≤ 500, MLogP ≤ 
4.15, nHBA ≤ 10 and nHBD ≤ 5) expected the three metal complexes 7-9, where the molecular 




In conclusion, we have synthesized the Mn(II), Co(II) and Ni(II) complexes of mixed isatin with 
3-(2-(aryl)hydrazono)acetylacetone 1-9. All the mixed ligand complexes were screened for their 
in vitro antibacterial activity. The evaluation showed that, among the tested complexes, the five 
complexes 3, 4, 5, 6 and 8 were the most active complexes against a panel of pathogenic tested 
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